Sugi Predict

Sugi Predict / Compounds / SCHEMBL3384869

SCHEMBL3384869

SCHEMBL3384869

CSc1ccccc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 2/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ HSD17B10 Q99714 1/20 0.56
▸ KMT2A Q03164 6/20 0.54
▸ MEN1 O00255 5/20 0.54
▸ TDP1 Q9NUW8 5/20 0.52
▸ SLC6A2 P23975 1/20 0.51
▸ SLC6A4 P31645 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ ALDH1A1 P00352 6/20 0.50
▸ MAPT P10636 4/20 0.50
▸ GAA P10253 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ ALPG P10696 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ KDM4A O75164 1/20 0.50
▸ TDP2 O95551 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.50
▸ APOBEC3G Q9HC16 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83607 0.85 PDE7A (0.53) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL31272173 0.84 PDE7A (0.78) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL224666 0.84 PDE7A (0.60) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL875772 0.84 PDE7A (0.78) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL18185040 0.84 TDP1 (0.67) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL9186731 0.83 PDE7A (0.56) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL28906800 0.83 ALDH1A1 (0.59) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL8667209 0.83 KMT2A (0.54) PDE7ASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3044275 0.82 TDP1 (0.48) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1
SCHEMBL6673312 0.82 PDE7A (0.50) PDE7ASMN1; SMN2HSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112062699-B Preparation method of o-aminothiophenol 苏州开元民生科技股份有限公司 2021-02-26 — — CN claimed
CN-112062699-A Preparation method of o-aminothiophenol 苏州开元民生科技股份有限公司 2020-12-11 — — CN claimed
CN-110105251-A A kind of industrialized preparing process of ortho-nitrophenyl sulfonic acid chloride 苏州市泽宸贸易有限公司 2019-08-09 — — CN claimed
CN-109251589-A Inorganic nano material ink and its preparation method and application, QLED device TCL集团股份有限公司 2019-01-22 — — CN claimed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 — — US claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 — — US claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 — — US claimed
US-20040230077-A1 Method of producing optically active sulfimide compound KYUSHU UNIVERSITY (JP) 2004-11-18 — — US claimed
EP-1452523-A2 Method of producing optically active sulfimide compounds KYUSHU UNIVERSITY (JP) 2004-09-01 — — EP claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 — — EP claimed
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) 2023-07-20 — — US disclosed
EP-4206196-A1 PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS Almirall S.A. (ES) 2023-07-05 — — EP disclosed
CN-115697993-A Pyrimidines as AXL inhibitors 南京正大天晴制药有限公司 2023-02-03 — — CN disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 — — EP disclosed
CN-110105251-A A kind of industrialized preparing process of ortho-nitrophenyl sulfonic acid chloride 苏州市泽宸贸易有限公司 2019-08-09 — — CN disclosed
EP-0335274-A2 Formation of nitrophenyl ethers from polyols and nitroanisoles THE DOW CHEMICAL COMPANY (US) 1989-10-04 — — EP disclosed
EP-0039312-B1 COLOUR PHOTOPGRAPHIC MATERIAL FOR THE SILVER-DYE BLEACHING PROCESS, PROCESS FOR THE PRODUCTION OF THIS MATERIAL AND ITS USE IN THE PRODUCTION OF PHOTOGRAPHIC IMAGES CIBA-GEIGY AG (CH) 1983-12-28 — — EP disclosed
US-4379819-A OIL SOLUBLE MONOAZO DYE CIBA-GEIGY AG (CH) 1983-04-12 — — US disclosed
EP-0039312-A1 Colour photopgraphic material for the silver-dye bleaching process, process for the production of this material and its use in the production of photographic images CIBA-GEIGY AG (CH) 1981-11-04 — — EP disclosed
US-4146688-A CHAIN EXTENSION BAYER AKTIENGESELLSCHAFT (DE) 1979-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040230077-A1 Method of producing optically active sulfimide compound TST, STS, ARSA PDE7A 3604/4885SMN1; SMN2 442/4885HSD17B10 2649/4885
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR AXL, FLT3, TYMP PDE7A 1146/4885SMN1; SMN2 3932/4885HSD17B10 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.